Skip to the page

Data / Drug companies / Kesin Pharma Corporation

Kesin Pharma Corporation: 61 products in the FDA NDC directory, labeler code 81033

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Kesin Pharma Corporation (labeler code 81033) lists 61 products in the FDA National Drug Code Directory, covering 45 finished drugs by generic name. By type: 43 prescription drugs, 18 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on February 27, 2026.

The request: Watch Kesin Pharma Corporation (FDA labeler code 81033): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
81033
Products in commercial distribution
61
Packages
93
Finished drugs by generic name
45
Prescription products
43
Over the counter products
18
Controlled substance products
Schedule IV 2, Schedule V 2
Flagged as original packager
22 of 22 products that carry the flag
Started marketing in the last 12 months
3
Earliest marketing start
September 21, 1976
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)4167.2%
Over the counter monograph drugs1423%
Other unapproved drugs46.6%
Authorized generics (NDA)11.6%
New drug applications (NDA)11.6%

Products by type

TypeProductsShare
Prescription drugs4370.5%
Over the counter drugs1829.5%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Solution2134.4%
Suspension1423%
Tablet, film coated813.1%
Tablet58.2%
Liquid58.2%
Powder, for solution23.3%
Ointment23.3%
Syrup11.6%
Powder, for suspension11.6%
Elixir11.6%
Granule, for solution11.6%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
CHILDRENS Acetaminophen81033-026SuspensionOver the counter monograph drugsFebruary 27, 2026
Atovaquone Oral Suspension81033-105SuspensionGeneric drugs (ANDA)February 6, 2026
Moxifloxacin81033-068Tablet, film coatedGeneric drugs (ANDA)December 12, 2025
Phenobarbital Oral Solution81033-164SolutionOther unapproved drugsNovember 5, 2025
Kesin MAG-AL Plus XS81033-007SuspensionOver the counter monograph drugsNovember 5, 2025
Kesin MAG-AL Plus81033-006SuspensionOver the counter monograph drugsNovember 5, 2025
Kesin MAG-AL81033-005SuspensionOver the counter monograph drugsNovember 5, 2025
Megestrol Acetate81033-150SuspensionGeneric drugs (ANDA)August 7, 2025
Gabapentin81033-124SolutionGeneric drugs (ANDA)August 6, 2025
Gabapentin81033-123SolutionGeneric drugs (ANDA)August 6, 2025
Gabapentin81033-123SolutionGeneric drugs (ANDA)August 6, 2025
Lacosamide Oral Solution81033-427SolutionGeneric drugs (ANDA)August 5, 2025
Hydroxyzine Hydrochloride81033-031SolutionGeneric drugs (ANDA)July 17, 2025
Lacosamide Oral Solution81033-428SolutionGeneric drugs (ANDA)July 14, 2025
Topiramate81033-035SolutionGeneric drugs (ANDA)July 7, 2025
Polyethylene Glycol 335081033-762Powder, for solutionGeneric drugs (ANDA)June 9, 2025
Mupirocin81033-032OintmentGeneric drugs (ANDA)May 28, 2025
Senna Syrup81033-120SyrupOver the counter monograph drugsMay 26, 2025
Magnesium Oxide81033-027TabletOver the counter monograph drugsApril 7, 2025
Guaifenesin81033-102LiquidOver the counter monograph drugsApril 1, 2025
Docusate Sodium Oral Liquid81033-022LiquidOver the counter monograph drugsApril 1, 2025
Sodium Citrate and Citric Acid81033-017SolutionOther unapproved drugsApril 1, 2025
Diphenhydramine HCl Oral Solution81033-029SolutionOver the counter monograph drugsMarch 4, 2025
Mineral Oil81033-042SolutionOver the counter monograph drugsMarch 1, 2025
Sodium Chloride81033-028TabletOther unapproved drugsMarch 1, 2025

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.